A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia

In chronic myeloid leukemia (CML) patients, 3-month BCR-ABL1 levels have consistently been correlated with further outcomes. Monitoring molecular responses in CML using the GeneXpert (Cepheid) platform has shown an optimal correlation with standardized RQ-PCR (IS) when measuring BCR-ABL1 levels lowe...

Descripción completa

Detalles Bibliográficos
Autores principales: García-Gutiérrez, Valentín, Gómez-Casares, María T., Puerta, José M., Alonso-Domínguez, Juan M., Osorio, Santiago, Hernández-Boluda, Juan C., Collado, Rosa, Ramírez, María J., Ibáñez, Fátima, Martín, María L., Rodríguez-Gambarte, Juan D., Martínez-Laperche, Carolina, Gómez, Montse, Fiallo, Dolly V., Redondo, Sara, Rodríguez, Alicia, Ruiz-Nuño, Concepción, Steegmann, Juan L., Jiménez-Velasco, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344481/
https://www.ncbi.nlm.nih.gov/pubmed/28278193
http://dx.doi.org/10.1371/journal.pone.0173532

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344481/
https://www.ncbi.nlm.nih.gov/pubmed/28278193
http://dx.doi.org/10.1371/journal.pone.0173532

Ejemplares similares